This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter          

Press Releases

Take a look at a selection of our recent media coverage:

SSRI for postnatal depression linked to lower risk of adverse maternal and child outcomes

4th September 2023

The use of postnatal selective serotonin reuptake inhibitor (SSRI) treatment is associated with a lower risk of postnatal depression-associated maternal mental health problems and child externalising behaviours, up to five years after childbirth, according to a recent study.

Published in the journal JAMA Network Open, the study sought to examine whether postnatal SSRI treatment moderated postnatal depression-associated maternal and child outcomes across early childhood years.

The UK and Norwegian researchers used longitudinal data from the Norwegian Mother, Father and Child Cohort Study, which recruited women during weeks 17 to 18 of their pregnancy and prospectively followed them after childbirth.

Mothers were asked to report any medications they had taken at postpartum month six. As SSRIs are commonly used for postnatal depression, the study focused exclusively on this class of drugs.

The outcomes of interest were self-reported maternal depression symptomology and relationship satisfaction from childbirth to five years after giving birth. In addition, child outcomes included emotional and behavioural problems such as internalising and externalising behaviours, attention deficit hyperactivity disorder (ADHD) symptoms, together with motor and language development at ages 18 months, three and five years.

Postnatal depression SSRI use

A total of 61,081 mother-child dyads met the criteria for a postnatal depression diagnosis. The analysis revealed that the severity was associated with higher levels of maternal depression across postpartum years 1.5 to five. There was also poorer relationship satisfaction between postpartum month six and year three.

Furthermore, postnatal depression severity was associated with higher levels of child internalising and externalising behaviours as measured across ages 18 months to five years, poorer motor and language development at years 18 months and three, as well as and ADHD symptoms at age five years.

In further analysis, the researchers observed postnatal SSRI treatment moderated associations between postnatal depression and maternal depression at postpartum year 1.5 and year five, together with better relationship satisfaction at both six months and three years after birth.

However, postnatal SSRI use also moderated the associations between postnatal depression and child externalising behaviours at ages 18 months and five years, as well as ADHD at age five years.

Dr Tom McAdams, senior author of the study and Wellcome Trust senior research fellow at King’s Institute of Psychiatry, Psychology and Neuroscience, said: ‘Postnatal depression is under-recognised and under-treated. It‘s critical that we view it as the severe mental illness that it is and ensure it is treated properly to mitigate some of the associated negative outcomes in mothers, children and wider family.

‘Our study found no evidence that SSRI treatment for mothers affected by postnatal depression was linked with an increased risk for childhood emotional difficulties, behavioural problems or motor and language delay.‘

SSRIs are designed to increase levels of the neurotransmitter serotonin, though, in recent years, this purported mode of action has been questioned.

Should the serotonin theory of depression be abandoned?

25th July 2022

The serotonin theory of depression should be discarded as there is no credible evidence to support it according to a recent review

The serotonin theory (ST) of depression should no longer be promoted as there is a distinct lack of credible supportive evidence according to the findings of a recent umbrella review by an international group based at the Division of Psychiatry, University College London, London, UK.

The selective serotonin re-uptake inhibitors (SSRIs) are a class of antidepressant drugs that include fluoxetine, citalopram and sertraline and commonly used in the treatment of depression. The mode of action of SSRIs is described as inhibition of the re-uptake of serotonin, thereby increasing activity of the neurotransmitter.

In other words, the concept of depression is predicated on the ST, i.e., low levels of the transmitter lead to depression although this premise has been challenged in recent years. Nevertheless, the concept of a chemical imbalance as an underlying cause of depression is a widespread belief among the general public and also, it seems among healthcare professionals.

In a survey of 66 UK general practitioners, 23% strongly agreed and 54% agreed that depression is caused by a chemical imbalance. Despite belief in the ST of depression, to date, no comprehensive review has synthesised the available evidence to either confirm or refute the theory.

For the present umbrella review, researchers examined the available literature to try and establish if there was credible support for the ST. In doing so, they focused on several specific areas that could provide evidence to support the theory.

They initially examined whether there were lower levels of both serotonin and 5-hydroxyindoleacetic acid (5-HIAA), its active metabolite, in body fluids among those with depression. Secondly, if there were alterations in the level of serotonin receptors. Thirdly, if levels of serotonin transporter (SERT) protein, which remove the transmitter from the synapse, were elevated in depression. Fourthly, whether tryptophan depletion (which also lowers serotonin levels) could induce depression and finally, the researchers looked at if there were elevated levels of the SERT gene in depressed patients.

Serotonin theory and supportive evidence

The researchers identified a total of 17 eligible studies for inclusion in their umbrella review.

Two meta-analyses with a total of 19 studies failed to provide evidence of an association between 5-HIAA levels and depression.

The team then focused on levels of the 5-HT1A receptor, an auto-receptor that inhibits the release of serotonin pre-synaptically. If depression is due to lowered levels of serotonin, the activity of this receptor should be enhanced although again, there was no evidence of a difference between depressed and control patients.

The SERT protein transports serotonin out of the synapse hence lowering levels. Consequently, were it to be responsible for depression, then the activity of the protein would be expected to be elevated in those with depression. There was no evidence to support this though interestingly, animal studies suggested that antidepressants actually reduced SERT.

Studies of tryptophan depletion (which in turn lowers serotonin) with healthy volunteers showed no effect on mood.

Finally, there was no apparent link between between genes and depression. In fact, one 2019 study concluded that the results suggest that early hypotheses about depression candidate genes were incorrect and that the large number of associations reported in the depression candidate gene literature are likely to be false positives.

Based on their findings, the authors concluded that it is time to acknowledge that the serotonin theory of depression is not empirically substantiated.

Moncrieff J et al. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry 2022.